ARTICLE | Clinical News
ABX464: Phase IIa started
June 6, 2016 7:00 AM UTC
Abivax began the double-blind, placebo-controlled, European Phase IIa ABX464-004 trial to evaluate 50 mg oral ABX464 once daily for 28 days with Prezista darunavir plus ritonavir or with Prezista plu...